Corpus ID: 212484133

Bioequivalence between two extended Release Tablets of Oxycodone Hydrochloride in Healthy Subjects under Fasting and Fed Conditions

@inproceedings{CFP2019BioequivalenceBT,
  title={Bioequivalence between two extended Release Tablets of Oxycodone Hydrochloride in Healthy Subjects under Fasting and Fed Conditions},
  author={Vespasiano CFP and Accennato VAC and M. Riccio and AC Noboli},
  year={2019}
}
  • Vespasiano CFP, Accennato VAC, +1 author AC Noboli
  • Published 2019
Bioavailability of different formulations of oxycodone 20 mg extended release tablets was compared in two bioequivalence studies, one under fasting conditions and the other one after a high-fat breakfast. Both studies were single dose, randomized, open label, and twoperiod crossover, with Brazilian male and female healthy subjects. Blood samples were taken during 48 h and plasmatic concentrations were determined using a validated UPLC-MS/MS method. Confidence intervals (CI90%) for the peak… Expand

Figures and Tables from this paper

References

SHOWING 1-8 OF 8 REFERENCES
Design and in vivo evaluation of oxycodone once-a-day controlled-release tablets
  • 10
  • PDF
Bioequivalence of oxycodone hydrochloride extended release tablets to marketed reference products OxyContin ® in Canad and US
  • Int J Clin Pharmacol Ther
  • 2013
Diário Oficial da União 24 de abril
  • 2006
Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products -General Considerations
  • United States Food and Drug Administration
  • 2002
Diário Oficial da União 22 de maio de
    Food Drug Administration (2014) Oxycontin® Label
      Guide for tests of relative bioavailability / bioequivalence of medicines